What is the prevalence of COVID-19 detection by PCR among deceased individuals in Lusaka, Zambia? A postmortem surveillance study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 12 2022
Historique:
entrez: 4 1 2023
pubmed: 5 1 2023
medline: 7 1 2023
Statut: epublish

Résumé

To determine the prevalence of COVID-19 postmortem setting in Lusaka, Zambia. A systematic, postmortem prevalence study. A busy, inner-city morgue in Lusaka. We sampled a random subset of all decedents who transited the University Teaching Hospital morgue. We sampled the posterior nasopharynx of decedents using quantitative PCR. Prevalence was weighted to account for age-specific enrolment strategies. Not applicable-this was an observational study. Prevalence of COVID-19 detections by PCR. Results were stratified by setting (facility vs community deaths), age, demographics and geography and time. Shifts in viral variants; causal inferences based on cycle threshold values and other features; antemortem testing rates. From 1118 decedents enrolled between January and June 2021, COVID-19 was detected among 32.0% (358/1116). Roughly four COVID-19+ community deaths occurred for every facility death. Antemortem testing occurred for 52.6% (302/574) of facility deaths but only 1.8% (10/544) of community deaths and overall, only ~10% of COVID-19+ deaths were identified in life. During peak transmission periods, COVID-19 was detected in ~90% of all deaths. We observed three waves of transmission that peaked in July 2020, January 2021 and ~June 2021: the AE.1 lineage and the Beta and Delta variants, respectively. PCR signals were strongest among those whose deaths were deemed 'probably due to COVID-19', and weakest among children, with an age-dependent increase in PCR signal intensity. COVID-19 was common among deceased individuals in Lusaka. Antemortem testing was rarely done, and almost never for community deaths. Suspicion that COVID-19 was the cause of deaths was highest for those with a respiratory syndrome and lowest for individuals <19 years.

Identifiants

pubmed: 36600354
pii: bmjopen-2022-066763
doi: 10.1136/bmjopen-2022-066763
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e066763

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Christopher J Gill (CJ)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA cgill@bu.edu.

Lawrence Mwananyanda (L)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

William B MacLeod (WB)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Geoffrey Kwenda (G)

Biomedical Sciences, University of Zambia, Ridgeway Campus, Lusaka, Lusaka, Zambia.

Rachel C Pieciak (RC)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Lauren Etter (L)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Daniel Bridges (D)

Program for Applied Technology in Health (PATH), Lusaka, Zambia.

Chilufya Chikoti (C)

Avencion Limited, Lusaka, Zambia.

Sarah Chirwa (S)

Avencion Limited, Lusaka, Zambia.

Charles Chimoga (C)

Avencion Limited, Lusaka, Zambia.

Leah Forman (L)

Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts, USA.

Ben Katowa (B)

Macha Research Trust, Choma, Southern Province, Zambia.

Rotem Lapidot (R)

Pediatric Infectious Diseases, Boston Medical Center, Brookline, Massachusetts, USA.

James Lungu (J)

Avencion Limited, Lusaka, Zambia.

Japhet Matoba (J)

Macha Research Trust, Choma, Southern Province, Zambia.

Gift Mwinga (G)

Avencion Limited, Lusaka, Zambia.

Benjamin Mubemba (B)

Wildlife Sciences, The Copperbelt University, Kitwe, Copperbelt, Zambia.

Zachariah Mupila (Z)

Avencion, Lusaka, Zambia.

Walter Muleya (W)

Biomedical Sciences, University of Zambia School of Veterinary Medicine, Lusaka, Lusaka, Zambia.

Mulenga Mwenda (M)

Program for Applied Technology in Health, Lusaka, Zambia.

Benard Ngoma (B)

Avencion Limited, Lusaka, Zambia.

Ruth Nakazwe (R)

Biomedical Sciences, University of Zambia University Teaching Hospital, Lusaka, Lusaka, Zambia.

Diana Nzara (D)

Avencion Limited, Lusaka, Zambia.

Natalie Pawlak (N)

Tufts University School of Medicine, Boston, Massachusetts, USA.

Lillian Pemba (L)

Avencion Limited, Lusaka, Zambia.

Ngonda Saasa (N)

University of Zambia School of Veterinary Medicine, Lusaka, Zambia.

Edgar Simulundu (E)

Macha Research Trust, Choma, Southern Province, Zambia.

Baron Yankonde (B)

Avencion Limited, Lusaka, Zambia.

Donald M Thea (DM)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH